02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
21:55 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

Transient nanotargeting

A team from the Fred Hutchinson Cancer Research Center has designed nanoparticles that introduce mRNA cargo to therapeutic cells in vitro , without requiring special instrumentation or causing the cell depletion or cytotoxicity that limits...
07:00 , Jun 23, 2016 |  BC Innovations  |  Translation in Brief

Musashi's dual duel

The Musashi genes were originally named for the samurai who fought with two swords because, when discovered in flies, their mutation created double-shafted bristles. Now, a pair of studies double down on the name, showing...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Tumor levels of Musashi homolog 2 (MSI2) as diagnostic marker for aggressive non-small cell lung cancer (NSCLC)

Biomarkers TECHNOLOGY: Tissue markers Tumor levels of MSI2 could help diagnose aggressive NSCLC. In human metastatic cell lines, MSI2 mRNA levels were higher than in human non-metastatic NSCLC cell lines. In NSCLC tumor samples from...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Acute myeloid leukemia (AML); chronic myeloid leukemia (CML) Musashi homolog 2 (MSI2) A study in mice and in humans suggests that antagonizing MSI2 could...
07:00 , Aug 19, 2010 |  BC Innovations  |  Targets & Mechanisms

Leukemia takes it up a NOTCH

The Notch pathway has been linked to aggressive growth in a range of tumor types but had not previously been considered a prime target for myeloid leukemia therapies. Separate American teams now have identified two...
07:00 , Aug 5, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Musashi homolog 2 (MSI2) Studies in cell culture and in mice suggest that antagonizing MSI2 could help prevent AML. In cultured...